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Abstract: Introduction: Medical cannabinoids have received significant mainstream media attention in
recent times due to an evolving political and clinical landscape. Whilst the efficacy of cannabinoids in
the treatment of some childhood epilepsy syndromes is increasingly recognized, medical cannabinoids
may also have potential clinical roles in the treatment of older adults. Prescribing restrictions for
medical cannabinoids in certain jurisdictions (including the UK) has recently been relaxed. However,
few geriatricians have the detailed knowledge or awareness of the potential risks or rewards of
utilizing cannabinoids in the older person; even fewer geriatricians have direct experience of using
these drugs in their own clinical practice. Older persons are more likely to suffer from medical
illness representing potential indications for medical cannabinoids (e.g., pain); equally they may be
more vulnerable to any adverse effects. Aim: This narrative literature review aims to provide a brief
introduction for the geriatrician to the potential indications, evidence-base, contra-indications and
side effects of medical cannabinoids in older people. Methods: A search was conducted of CENTRAL,
Medline, Embase, CINAHL and psycINFO, Cochrane and Web of Science databases. Reference lists
were hand searched. Abstracts and titles were screened, followed by a full text reading of relevant
articles. Results: 35 studies were identified as relevant for this narrative review. Conclusions:
Cannabinoids demonstrate some efficacy in the treatment of pain and chemotherapy-related nausea;
limited data suggest potential benefits in the treatment of spasticity and anxiety. Risks of cannabinoids
in older patients appear to be moderate, and their frequency comparable to other analgesic drug classes.
However, the quality of research is weak, and few older patients have been enrolled in cannabinoid
studies. Dedicated research is needed to determine the efficiency and safety of cannabinoids in
older patients.
Keywords: cannabinoids; elderly; THC; CBD; effectiveness; safety; literature review
1. Introduction
Medical cannabinoids have received significant attention in recent years, owing to legal changes
in the status of the drugs for medicinal use in various European and North American jurisdictions.
Despite this, few European clinicians have experience in the prescription of medical cannabinoids;
this is partly attributable to a lack of experience around indications and side effect profiles. In this
narrative review, we aim to provide a summary of the current evidence pertaining to the use of medical
cannabinoids and any potential risks which must be considered in the older person.
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Although the criminalization of cannabis has historically hindered robust scientific research,
cannabis for medical use is now legal in 11 European Union (EU) states, Australia, Canada, Israel and
31 of the 52 states within the USA. As a result, evidence of its efficacy and side effects is emerging,
and may inform future medicinal use.
To date, the majority of cannabinoid research has focused upon a healthy younger population,
free from frailty and major comorbidity. However, advancing age is unequivocally associated with
the accumulation of medical comorbidity and individual disease states, such as cancer. It is therefore
clear that older persons may become an important group of potential cannabinoids users in the future.
Greater awareness amongst geriatricians of the potential indications and hazards of cannabinoids in
the older patient is therefore imperative.
2. Background
The medicinal properties of cannabis have been recognized since at least 1500 BC, when the
drug was listed in the ancient Chinese pharmacopeia as a treatment for rheumatic pain [1]. In the
mid-nineteenth century, cannabis smoking was introduced into western medicine as a treatment for
rheumatism, before becoming prohibited in the UK in 1925 for general use and in 1971 for medicinal use.
Plants of the cannabis family contain two major cannabinoids: tetrahydrocannabinol (THC) and
cannabidiol (CBD). THC is the primary psychoactive compound, and appears to have neuroprotective,
anti-inflammatory, anti-emetic and analgesic effects. CBD has no psychoactive properties, and appears
to attenuate the psychoactive properties of THC when used in combination. CBD in isolation reduces
proinflammatory cytokine release and displays antioxidant properties [2].
Two strains of the cannabis plant (sativa and indica) are considered to be of potential medical use.
Each strain has different properties, with the THC:CBD ratio determining their clinical effects. This
ratio is used to classify cannabis plants according to chemical constitution, with 3 chemotypes currently
recognized [3]. Chemotype-1 plants are those which contain the highest concentration of THC, and are
used recreationally due to their potency and psychotropic effects.
In humans, cannabinoids act via the modulation of the endocannabinoid system, which consists
of CB1 and CB2 cannabinoid receptors. The expression of CB1 and CB2 receptors varies between
tissues; CB1 receptors are primarily located within the central nervous system (CNS); CB2 receptors
are abundant in the peripheral tissues and appear to have a greater effect upon cytokine action and
modulation of the immune system [4]. THC and CBD differ in their affinity to CB1 and CB2 receptor
agonists; THC has an affinity for both receptors, whereas CBD has more selective affinity for CB2
receptors. The physiological function of the endocannabinoid system remains incompletely understood.
However, current research suggests that this system is involved in: neuroprotection, nociception,
autonomic tone, immune function, connective tissue repair, satiety and behavior [5].
3. Aims
It is important to recognize that the heterogeneity and quality of the research methodology in
this field makes interpretation of research in this area problematic. Firstly, it should be noted that
analysis of the efficacy or safety of smoke inhalation is methodologically challenging, due to the
uncertain composition of smoked cannabis. Importantly, illicit recreational cannabis strains have been
selectively bred to increase THC concentrations (“skunk”) resulting in augmented neuropsychiatric
side effect profiles.
These recreational agents receive considerable attention in the mainstream media, but their
toxicity should not necessarily be assumed to be transferrable to the standardized production of
medicinal cannabinoids, and their use in a medical context in a controlled jurisdiction [6]. Secondly,
the heterogeneity of cannabinoid products, the mode of administration, and disparate population group
makes a systematic review in this context of limited value; it is highly unlikely that firm conclusions
would be possible from the quality and quantity of evidence currently available in the older adult.
This narrative literature review therefore aims to provide a concise introduction and summary for the
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geriatrician. It aims to provide an overview of potential indications, contra-indications and probable
side effects of medical cannabinoids in older people.
4. Methods
In order to minimize the bias in our narrative review, a literature search was conducted in
April 2019. Bibliographic databases that were searched included: CENTRAL, Medline, Embase,
CINAHL and PsycINFO. Further database searches included: the Cochrane Library and Web of Science.
Relevant, unpublished literature was also sought through clinicaltrials.gov and the International
Clinical Trials Registry Platform (ICTRP). Finally, for completeness, the reference lists of relevant
studies and systematic reviews were hand-searched for additional references.
All databases were searched using a unique combination of MeSH terms and title key-word
searches. MeSH terms included: “Cannabinoid OR Cannabis OR Medical marijuana” AND “Aged
or Geriatrics”. Keywords were then added, where appropriate, to improve the scope of the search,
and included: “CBD OR THC OR Epidiolex OR Nabilone OR Nabiximol* OR Sativex” AND “Old
OR Elderly OR Age* OR Geriatric*”. These keywords and MeSH terms were combined with the
appropriate Boolean operator within each database to form a comprehensive search strategy.
Where possible, in each database, additional search restrictions were applied to ensure an adequate
focus, which included: human studies, elderly population, publication in the last 20 years and
publication in the English language.
5. Results
The database search yielded 581 results. A further 22 records were identified through other sources.
Title and abstract screening were conducted by two independent researchers. Any discrepancies of
the inclusion decision were resolved through discussion. Following the screening process, 57 articles
remained. All were read in full by the primary author. Following full text reading, 38 were deemed
relevant for this review. The main findings of these studies can be found in Table 1. This selection
process is illustrated below in Figure 1.
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Table 1. Search results main findings.
Author Year Study Type Main Findings
Minerbi A. [7] 2019 Review
Evidence for efficacy is sparse, and considerable
adverse effects have been documented on cognitive,
cardiovascular and gait function.
McMaster University [8] 2019 RCT protocol
Protocol for a trial that will assess the efficacy of CBD
versus a placebo for post-operative pain following
knee arthroplasty.
Van Den Elsen G. [9] 2019 RCT THC had no significant effect on neuropsychiatricsymptoms, but was well tolerated by participants.
Beauchet O. [10] 2018 Mini review
Some studies report improved outcomes. However,
studies are not focusing on an elderly population, and
are of limited quality, making any conclusions difficult
to draw.
Abuhasira R. [11] 2018 Prospective study
Therapeutic cannabis is both effective and safe in an
elderly population. In particular, its ability to reduce
other prescriptions, such as opioids, is advantageous.
Agornyo P. [12] 2018 Survey
Regular cannabis use in older patients resulted in
reduced pain, reduced medication side effects and the
discontinuation of other pain medications.
Briscoe [13] 2018 Review
The volume of current research is increasing, but there
is still insufficient evidence to make
robust recommendations.
Mücke M. [14] 2018 Systematic review The risks of cannabinoid treatments for neuropathicpain appear to outweigh any potential benefits.
Torres-Moreno M. [15] 2018 Systematic Review
Results favored cannabinoids over the placebo.
However, there is little evidence to suggest that
cannabinoids are effective for bladder dysfunction,
pain and spasticity in MS patients.
Grayson L. [16] 2018 Case report Observed reaction between cannabidiol and warfarin.INR more than doubled.
Stockings E. [17] 2018 Systematic Review
The effectiveness of cannabinoids is minimal for
non-cancer pain. Studies show very high NNT
for cannabinoids.
Mahvan T.D. [18] 2017 Review There are considerable risks for elderly patients usingcannabis, especially those with comorbidities.
Katz I. [19] 2017 Review
For Parkinson’s Disease (PD), cannabis can be useful
as a last resort. For dementia, cannabis can help with
behavioral problems. Sleep disturbance and weight
loss are also areas of potential benefit from cannabis.
Bellnier T. [20] 2017 Retrospective study Cannabis led to improved quality of life, reduced pain,reduced opioid use and led to reduced costs.
Hansra D.M. [21] 2017 Survey Dronabinol led to significant improvements in QoL,appetite and anxiety, amongst cancer patients.
Schimrigk S. [22] 2017 RCT
Dronabinol was non-significantly better at reducing
pain in MS patients. However, Dronabinol was
associated with much higher rates of adverse events.
Lim K. [23] 2017 Systematic Review
Studies indicate that cannabinoids could potentially
benefit anxiety, psychotic symptoms, PTSD and
dyskinesia in PD.
Stampanoni M. [24] 2017 Review The evidence for cannabinoids in PD patients iscurrently inconclusive.
Tafelski S. [25] 2016 Systematic review ofsystematic reviews
Cannabinoids should not be recommended for
chemotherapy-induced nausea and vomiting, as either
a first- or second-line treatment. Anti-emetics are
currently superior.
Ahmed A.I. [26] 2015 RCT
THC was well tolerated by elderly participants with
dementia. There were more adverse events within the
placebo group. Adverse events experienced by THC
users were most commonly: dizziness, fatigue
and agitation.
Smith L.A. [27] 2015 Systematic review Cannabinoids may have potential at reducingchemotherapy-induced nausea and vomiting.
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Table 1. Cont.
Author Year Study Type Main Findings
Liu C. [28] 2015 Review
Some studies show significant improvement in
agitation and aggression in Alzheimer’s
Disease (AD) patients, but evidence is
insufficient to make robust conclusions.
van den Elsen G.A. [29] 2014 Systematic Review
Studies show that THC may be useful for
anorexia and behavioral symptoms in
dementia. Adverse symptoms were common in
the cannabinoid groups, with sedation being
the most frequent.
Ahmed A.I. [30] 2014 RCT
THC was associated with more adverse events
than placebo. Increasing the dose of THC
increased the frequency of adverse events.
Lotan I. [31] 2014 Open label study Smoking cannabis significantly improved sleepand reduced pain in PD patients.
Chagas M.H. [32] 2014 RCT
Cannabidiol had no significant impact upon
PD symptoms, but showed an improved
quality of life (QoL).
Ahmed A.I. [33] 2014 Letter
There is scanty evidence for the safety and
effectiveness of cannabis and cannabinoids in
the elderly. We also cannot extrapolate results
from the studies of younger individuals onto
an elderly population.
Wolff V. [34] 2013 Case series It is highly likely that there is an associationbetween cannabis and stroke.
Yamaori S. [35] 2012 In vitro study THC and CBD both inhibited CYP2C9 activity.
Bergamaschi M. [36] 2011 RCT CBD significantly reduced anxiety inparticipants giving public speeches.
Patel T. [37] 2010 Review
Cannabinoid agonists have been shown to
reduce chronic pruritis in patients with atopic
dermatitis, lichen simplex, prurigo nodularis,
and CKD-related itching.
Fusar-Poli P. [38] 2009 RCT
CBD reduces autonomic responses to fear,
whereas THC augments the
autonomic response.
Narang S. [39] 2008 RCT
Dronabinol resulted in additional pain relief for
individuals already using opioids for
noncancer-related chronic pain.
Strasser F. [40] 2006 RCT
THC and cannabis extract were no better than
the placebo at increasing appetite or QoL for
patients with cancer-related cachexia.
Sutton L.M. [41] 2003 Review
Cannabinoids can be useful for dyspnoea at the
end of life. However, there must be caution
with these agents due to the psychotropic effect
and reflex tachycardia and hypotension.
Jatoi A. [42] 2002 RCT
Megestrol acetate performed better than
dronabinol for palliating anorexia in
cancer patients.
Sieradzan F. [43] 2001 RCT Nabilone significantly reduced dyskinesias inPD patients.
Yeh S. [44] 1999 Review
Anecdotal evidence has shown Dronabinol to
be effective at increasing appetite in HIV
patients and Alzheimer’s patients.
Volicer L. [45] 1997 RCT Body weight increased more within thedronabinol group than with the placebo.
6. Potential Indications for Medicinal Cannabinoids in the Older Person
In addition to smoked cannabis, there are currently three cannabinoid preparations which are in
widespread use, namely, nabilone, dronabinol and nabiximols (Sativex).
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7. Pain
7.1. Smoked Cannabis
Although smoked cannabis is widely known to be used by individuals as self-administered
analgesia, this route of administration is difficult to study robustly; limited data are therefore available
to support this mode of drug delivery. To address this, a 2010 randomized controlled trial was
conducted to assess the efficacy of smoked cannabis within a population of patients suffering from
chronic neuropathic pain. This study found a dose–response relationship between the potency of
inhaled cannabis and pain amelioration, demonstrating a statistically significant improvement in
average daily pain scores between the highest potency and control groups [46].
7.2. Nabilone
Nabilone is a synthetic analogue of THC. It is currently endorsed in the UK by NICE for
chemotherapy-induced nausea and vomiting refractory to other treatment [47]. However, it has also
been reported to display analgesic properties. In 2017, the Canadian Agency for Drug and Technologies
in Health (CADTH) published a critical appraisal for Nabilone use in chronic pain [48]. CADTH
concluded that, although there are limitations in the current evidence base, Nabilone can improve pain,
with limited associated harms.
This conclusion was largely based upon the results of a 2015 systematic review, which examined
four studies evaluating nabilone for chronic pain in diabetic neuropathy, multiple sclerosis, fibromyalgia
and a medication-overuse headache. In all conditions except fibromyalgia, Nabilone was found to be
superior to control for improving pain. CADTH also cited a further study, relevant to this review, in
which the average participant was aged 64 years. However, this study found that in post-radiation
neuritis, there was no significant improvement observed.
7.3. Dronabinol
Dronabinol is a synthetic THC analogue that has been approved for pain control in some
jurisdictions. Narang et al. reported the effect of dronabinol on pain in a placebo-controlled trial [39].
In this study, dronabinol was used as an adjuvant to opioids with a significant reduction in pain at
8 hours noted in the dronabinol arm. These findings continued into the second open-label phase of the
trial, where a statistically significant reduction in the pain score was observed from baseline in the
dronabinol arm. However, other trials have not been able to reproduce these results over a longer
follow up period [22].
7.4. Nabiximols
Unlike the THC analogue nabilone and dronabinol, Nabiximols is a whole plant extract of
cannabis, containing both THC and CBD. It is currently licensed for the treatment of multiple sclerosis
(MS)-associated spasticity and as an adjuvant for cancer pain treated with opioids.
In both Israel and Canada, nabiximols has also been licensed for neuropathic pain in multiple
sclerosis. CADTH has also published a critical appraisal of THC–CBD combination buccal sprays used
for chronic neuropathic or non-cancerous pain [49]. The five systematic reviews cited by CADTH
provided conflicting evidence: some reported significant improvement in pain, others no improvement.
CADTH reached the conclusion that short-term benefits can be seen with the use of nabiximols for
patients with chronic-neuropathic or non-cancer pain, but evidence for its continued use is unclear.
Further recent evidence evaluating the use of cannabinoids for treating non-cancer pain can be
derived from a 2018 systematic review. This included 104 randomized and non-randomized trials
reporting on cannabinoid use for pain. A total of 45 RCTs assessed the impact of cannabinoids on
altering pain intensity. 30 studies were included in a meta-analysis, which found that cannabinoid
treatment resulted in a significantly greater pain reduction than controls [17].
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A recent Cochrane review also found that cannabis-based products were more effective than the
placebo at reducing pain severity. However, the lack of high-quality evidence was noted, guarding the
grade of recommendations [14]. It is important to appreciate that no studies have specifically aimed to
evaluate the effect of these drugs on pain in older people. Extrapolation of adult data to older adults is
therefore largely speculative, and dedicated research in this group is indicated.
8. Chemotherapy Related Nausea
The use of cannabinoids to manage chemotherapy-related nausea is relatively well researched.
A recent Cochrane systematic review and meta-analysis found that cannabinoids were effective and
performed better than the placebo [27]. Cannabinoids have also been shown to display equal efficacy
when compared to conventional antiemetic drugs, albeit with an increased side effect profile including
dizziness, sedation and dysphoria [25]. Notwithstanding the side effect profile, cannabinoids may
have a role to play in refractory chemotherapy-induced nausea.
9. Spasticity
Spasticity is a common consequence of stroke and other primary neurological disorders.
Epidemiological evidence indicates that 20% of patients suffering from Multiple Sclerosis (MS)
have used cannabis to ease their symptoms of stiffness [50].
A 2018 systematic review in MS patients found that cannabinoids reduced self-reported spasticity
compared to the control; these self-reported findings were not however reflected in the objective
spasticity scores [15]. It remains unclear whether cannabinoids have a role to play in the management
of spasticity due to MS, or other neurological injury.
10. Appetite Stimulation
The evidence for appetite stimulation in the context of cancer-induced anorexia is currently limited.
A 2002 trial compared the cannabis extract dronabinol to megestrol (synthetic progestin). This study
found that dronabinol was less effective than megestrol at appetite stimulation and inducing weight
gain [42]. Similarly, a 2006 trial by the Cannabis in Cachexia Study group was terminated due to
insufficient differences between the study arms of: (1) cannabis extract, (2) tetrahydrocannabinol and
(3) placebo [40]. Currently therefore, there is no evidence to indicate that cannabinoids have any effect
upon cancer-induced anorexia.
Anorexia in the elderly is complex, and the mechanisms underlying the anorexia of ageing may
be distinct to the anorexia of dementia or cancer. Few trials have evaluated the efficacy of cannabis
products for anorexia associated with ageing or dementia. A small placebo-controlled cross-over trial
found measurable changes in weight gain and decreased agitation with dronabinol [45]. However, this
study was limited by small numbers of patients at its follow-up, and at present the European Society
for Clinical Nutrition and Metabolism has concluded that there is currently no evidence to support the
use of cannabinoids in the cachexia of dementia [51].
Further work is required to determine whether cannabinoids have any role in stimulating appetite
and weight gain in patients with anorexia related to underlying dementia.
11. Behavioral Problems in Dementia
The neuropsychiatric symptoms of dementia have been evaluated in one double-blind
placebo-controlled study. This found that although THC administration was well tolerated, it
had no effect on neuropsychiatric symptoms when compared to the placebo. However, the authors did
speculate that due to the tolerability of side effects, further work was required to assess the efficacy of
higher doses [9].
Two systematic reviews have also been published in this field [23,28]. When pooled, these reviews
included five studies which assessed dronabinol; 1 assessing nabilone; 2 THC. All studies assessing
dronabinol and nabilone reported improvements in behavioral symptoms; neither studies assessing
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THC demonstrated improvements. Dronabinol and nabilone may therefore have a potential role in
dementia-related behavioral problems.
The safety and tolerability of cannabinoids in dementia has also been evaluated further [26].
One study evaluated the safety of oral THC through monitoring adverse events and vital signs over
12 weeks. During follow up, there were fewer adverse events within the THC group compared to
placebo control. Furthermore, only six cases of adverse events were attributed to THC use, all of which
were considered to be mild in nature. These adverse events included: agitation, dizziness and fatigue.
From these data, the authors concluded that cannabinoid use has a tolerable safety profile in older
people with dementia, with doses of up to 5 mg/day being less likely to induce adverse effects.
12. Anxiety
Anxiety disorders increase with age and are associated with increased healthcare needs and social
isolation [52].
Patients taking recreational cannabis report conflicting findings in relation to anxiety. This may be
characterized by a curtailment of their anxiety, but also potential augmentation and paranoid thought.
This paradoxical observation is thought to be a reflection of the differing CBD:THC ratios present in the
smoked plant extract; in general CBD is thought to reduce anxiety, with THC having an antagonistic
effect [1].
A 2009 randomized, double-blind, placebo-controlled study found that CBD administration was
associated with diminished autonomic arousal on fMRI and a reduced anxiety state; conversely a state of
increased autonomic arousal and increased anxiety was found with THC administration [38]. A further
randomized control trial conducted in seasonal affective disorder patients found that the administration
of CBD prior to the introduction of anxious stimuli significantly reduced anxiety [36]. CBD may have
potential for diminishing anxiety in both pathological and non-pathological anxiety states.
13. Movement Disorders
A 2014 open label study found that 30 min after smoking cannabis, patients reported improvements
in the major symptoms of Parkinson’s Disease (PD), including: rigidity, tremor, pain, sleep and
bradykinesia [31]. This study design displays many methodological problems which render the results
challenging to interpret. However, further exploration of the use of smoked cannabis for the treatment
of PD is warranted.
A 2017 review consisting of four randomized, double-blind, placebo-controlled trials further
evaluated the effect of cannabinoids in PD [24]. Two trials detected positive outcomes for the use of
cannabinoids in PD; two did not. One study detected a significant reduction in levodopa-induced
dyskinesia and rush dyskinesia [43]. Significant improvements in the Parkinson’s disease questionnaire
(PDQ-39) and activities of daily living scores were also reported [32]. Subsequent studies have not
been able to replicate these findings. Further work is required to determine whether cannabinoids
affect the symptoms of movement disorders.
14. Potential Hazards of Medical Cannabinoids in Older Adults
14.1. Smoked Cannabis
We are unaware of any RCTs that assess the safety of smoked cannabis in an elderly population.
One observational study has found that cannabis smoking in elderly individuals was associated with
emergency department attendance and injury [53]. More generally, smoked cannabis had been linked
to an increased risk of psychosis and neurocognitive dysfunction in younger adults and adolescents,
though the relevance of these observations in older adults is currently unknown [54]. In the context of
reduced neurocognitive reserve, it seems plausible that older adults are likely to be at increased risk of
neurocognitive side effects.
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14.2. Nabilone
Nabilone’s safety is also poorly documented in an elderly population. A case series observed the
side effects of using nabilone in elderly patients with neuropsychiatric symptoms. This study observed
sedation as the primary side effect in this population [55].
14.3. Dronabinol
The safety of Dronabinol in an elderly population has only been observed in two studies [45,54].
These studies found that the most common side effects were sedation, anxiety, emotional labiality,
fatigue, somnolence and euphoria. A serious side effect of a single patient experiencing a grand mal
seizure was also observed [56].
14.4. Nabiximols
Currently no studies specifically address the safety of nabiximols in an elderly population.
However, adult data indicate more adverse events in the nabiximols group compared to placebo [57].
The most common adverse events reported were: asthenia, vertigo and nausea, and it seems plausible
that these side effects may be applicable to older patients
15. Safety and Adverse Effects
Despite numerous small studies describing a modest side effect profile of cannabinoids, we are
aware of only one systematic review evaluating the safety profile of cannabis and cannabis products in
the elderly [29]. This systematic review found that cannabinoids were associated with a higher rate of
adverse events than the control.
The most common side effects experienced by users of cannabinoids included drowsiness, dry
mouth, coordination disturbance and headache [30]. However, no severe adverse events were reported
in this review, and only 1.4% of participants discontinued treatment due to adverse effects.
A more recent prospective study addressed the safety and efficacy of cannabis specifically in older
subjects [11]. This study reported that in the 6-month follow up period, 31.7% of the cohort experienced
at least one side effect. The most common side effect experienced was dizziness (9.7%). Others included
confusion or disorientation (1.9%) and hallucinations (0.8%). The rate of falls amongst participants
receiving cannabinoids was not elevated despite these side effects: 53.4% of the 515 participants
reported at least one fall in the 6 months before cannabis treatment, with only 21.9% reporting a fall in
the 6 months after initiating treatment. However, there are no data reporting the respective frailty of
individuals enrolled in this trial, and the clinical impact of increased dizziness in persons vulnerable to
falls is currently unknown.
Notably, the participants of this study smoked cannabis plants with heterogenous THC: CBD
formulations. Although there was a predominance of THC-dominant strains used, different
formulations reduce the reliability and application of this data to a wider population.
16. Medication Interaction
Cannabinoids including THC and CBD are both metabolized through different isoforms of the P450
enzyme system. Cannabinoids therefore may compete with other drugs which are metabolized through
this pathway [16]. Notably, five of the seven P450 isoforms that metabolize CBD also metabolize
warfarin. Cannabinoid use may therefore increase serum warfarin concentration and bleeding risk.
Despite an in vitro study confirming this interaction, there is currently only one case report citing this;
it is therefore currently unclear what the clinical significance of drug interaction may be in recreational
users. However, in the context of regular medication for chronic illness, this may become of more
clinical importance [35]. Other drug classes that may potentially be influenced by competition for
cytochrome P450 metabolism are listed in Table 2.
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Table 2. Common CYP2C9 substrates.
1. Anti-inflammatory drugs e.g., ibuprofen
2. Anti-convulsant drugs e.g., phenytoin
3. Asthma drugs e.g., zafirlukast
4. Anti-cancer drugs e.g., cyclophosphamide
5. Hypoglycemic drugs e.g., glimepiride
6. Anticoagulants e.g., warfarin
7. ACE inhibitors e.g., losartan
17. Long Term Safety
The World Health Organization (WHO) recognizes that recreational cannabis use is associated
with significant cardiovascular risks. These effects are less well explored in the context of medicinal
cannabis. A 2017 systematic review found that in individuals with pre-existing cardiovascular disease,
the greatest risks posed by cannabis products were ischemic strokes or myocardial infarctions [34],
though wide scale data evaluating this area is currently absent. It has been suggested that cannabinoids
may be associated with an increase in the risk of solid tumor neoplasia. At present to our knowledge,
no definite data exist to confirm this.
Although it is clear that the side effect profile of cannabinoids is inadequately understood at
present, it is likely to be significant, especially in older people who have to date been excluded from
clinical trials in this field. Notwithstanding this current clinical uncertainty, it is important to reflect
that the side effect profiles of other drug classes necessarily used in older adults (e.g., opiates, NSAIDS,
anticonvulsants) are equally problematic. Limited data indicate that cannabinoids may potentially
reduce the opiate requirements in some pain settings, or facilitate withdrawal from opiates in their
entirety [11]. Further dedicated research in the frail, older patient is urgently warranted to quantify the
risks and potential benefits.
18. Conclusions
Cannabinoids appear to demonstrate some moderate efficacy in the treatment of pain and
chemotherapy-related nausea; there are limited data to suggest any possible benefits in the treatment
of spasticity and anxiety. However, the quality of research in this area is weak and derived from
heterogeneous interventions and study populations, making interpretation of the sparse literature in
this field difficult.
The existing evidence base appears to indicate that the risks of cannabinoids in older persons are
modest, but not insignificant. High quality research is urgently needed to further determine the efficacy
and side effect profile of cannabinoids in older persons and compare them to current alternatives.
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